UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 116

Sortiert nach

Overview of myelin, major myelin lipids, and myelin-associated proteins

Frontiers in chemistry, 2023-02, Vol.10, p.1041961-1041961

2023

Link zum Volltext

Verfügbarkeit prüfen

Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies

Current neurology and neuroscience reports, 2021-07, Vol.21 (7), p.36-36, Article 36

2021

Link zum Volltext

Verfügbarkeit prüfen

Multiple Sclerosis Severity Score: Concept and applications

Multiple sclerosis, 2020-04, Vol.26 (5), p.548-553

2020

Link zum Volltext

Verfügbarkeit prüfen

The Expanding Clinical Spectrum of Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Associated Disease in Children and Adults

Frontiers in neurology, 2020-09, Vol.11, p.960-960

2020

Link zum Volltext

Verfügbarkeit prüfen

Which symptoms contribute the most to patients’ perception of health in multiple sclerosis?

Multiple sclerosis journal - experimental, translational and clinical, 2017-09, Vol.3 (3), p.2055217317728301-2055217317728301

2017

Link zum Volltext

Verfügbarkeit prüfen

Longitudinal study of multiple sclerosis lesions using ultra-high field (7T) multiparametric MR imaging

PloS one, 2018-09, Vol.13 (9), p.e0202918-e0202918

2018

Link zum Volltext

Verfügbarkeit prüfen

Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder

Current Allergy and Asthma Reports, 2016-06, Vol.16 (6), p.42-42, Article 42

2016

Link zum Volltext

Verfügbarkeit prüfen

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study

Journal of neurology, neurosurgery and psychiatry, 2016-10, Vol.87 (10), p.1133-1137

2016

Link zum Volltext

Verfügbarkeit prüfen

Serious safety events in rituximab‐treated multiple sclerosis and related disorders

Annals of clinical and translational neurology, 2020-09, Vol.7 (9), p.1477-1487

2020

Link zum Volltext

Verfügbarkeit prüfen

Two cases of MT-ND5-related mitochondrial disorder misdiagnosed as seronegative neuromyelitis optica spectrum disorder

Multiple sclerosis, 2023-06, Vol.29 (7), p.892-897

2023

Link zum Volltext

Verfügbarkeit prüfen

Linear scleroderma "en coup de sabre" with extensive brain involvement-Clinicopathologic correlations and response to anti-Interleukin-6 therapy

Orphanet journal of rare diseases, 2019-05, Vol.14 (1), p.110-7, Article 110

2019

Link zum Volltext

Verfügbarkeit prüfen

Short-term disability progression in two multiethnic multiple sclerosis centers in the treatment era

Therapeutic advances in neurological disorders, 2018-01, Vol.11, p.1756286418793613-1756286418793613

2018

Link zum Volltext

Verfügbarkeit prüfen

Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS – YES

Multiple sclerosis, 2017-08, Vol.23 (9), p.1188-1190

Kister, Ilya

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosis

Therapeutic advances in neurological disorders, 2016-11, Vol.9 (6), p.454-461

2016

Link zum Volltext

Verfügbarkeit prüfen

Ultrahigh-Field MR (7 T) Imaging of Brain Lesions in Neuromyelitis Optica

Multiple Sclerosis International, 2013-01, Vol.2013, p.398259-7

2013

Link zum Volltext

Verfügbarkeit prüfen

Magnetic Resonance Phase Alterations in Multiple Sclerosis Patients with Short and Long Disease Duration

PloS one, 2015-07, Vol.10 (7), p.e0128386-e0128386

2015

Link zum Volltext

Verfügbarkeit prüfen

Cervical spinal cord atrophy in NMOSD without a history of myelitis or MRI-visible lesions

Neurology : neuroimmunology & neuroinflammation, 2016-06, Vol.3 (3), p.e224

2016

Link zum Volltext

Verfügbarkeit prüfen

Spinal dural fistula and anterior spinal artery supply from the same segmental artery: Case report of volumetric T2 MRI diagnosis and rational endovascular treatment

Interventional neuroradiology, 2019-10, Vol.25 (5), p.579-584

2019

Link zum Volltext

Verfügbarkeit prüfen

Disease exacerbation after rituximab induction in neuromyelitis optica

Neurology : neuroimmunology & neuroinflammation, 2015-02, Vol.2 (1), p.e61-e61

2015

Link zum Volltext

Verfügbarkeit prüfen

Hybrid and vaccine‐induced immunity against SAR‐CoV‐2 in MS patients on different disease‐modifying therapies

Annals of clinical and translational neurology, 2022-10, Vol.9 (10), p.1643-1659

2022

Link zum Volltext

Verfügbarkeit prüfen

Tension-type Headache and Migraine in Multiple Sclerosis

Current pain and headache reports, 2010-12, Vol.14 (6), p.441-448

2010

Link zum Volltext

Verfügbarkeit prüfen

Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder

Neurologic clinics, 2021-02, Vol.39 (1), p.35-49

2021

Link zum Volltext

Verfügbarkeit prüfen

Pushing the boundaries of neuromyelitis optica: does antibody make the disease?

Neurology, 2015-07, Vol.85 (2), p.118

2015

Link zum Volltext

Verfügbarkeit prüfen

Author response: Reducing costs while enhancing quality of care in MS

Neurology, 2017-03, Vol.88 (12), p.1212

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 116

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(99)
Mit Volltextzugriff
(98)

Publikationsform

Artikel
(111)
Berichte
(5)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Overview of myelin, major myelin lipids, and myelin-associated proteins

Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies

Multiple Sclerosis Severity Score: Concept and applications

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study

The Expanding Clinical Spectrum of Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Associated Disease in Children and Adults

Which symptoms contribute the most to patients’ perception of health in multiple sclerosis?

Longitudinal study of multiple sclerosis lesions using ultra-high field (7T) multiparametric MR imaging

Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study

Serious safety events in rituximab‐treated multiple sclerosis and related disorders

Two cases of MT-ND5-related mitochondrial disorder misdiagnosed as seronegative neuromyelitis optica spectrum disorder

Linear scleroderma "en coup de sabre" with extensive brain involvement-Clinicopathologic correlations and response to anti-Interleukin-6 therapy

Short-term disability progression in two multiethnic multiple sclerosis centers in the treatment era

Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS – YES

Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosis

Ultrahigh-Field MR (7 T) Imaging of Brain Lesions in Neuromyelitis Optica

Magnetic Resonance Phase Alterations in Multiple Sclerosis Patients with Short and Long Disease Duration

Cervical spinal cord atrophy in NMOSD without a history of myelitis or MRI-visible lesions

Spinal dural fistula and anterior spinal artery supply from the same segmental artery: Case report of volumetric T2 MRI diagnosis and rational endovascular treatment

Disease exacerbation after rituximab induction in neuromyelitis optica

Hybrid and vaccine‐induced immunity against SAR‐CoV‐2 in MS patients on different disease‐modifying therapies

Tension-type Headache and Migraine in Multiple Sclerosis

Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder

Pushing the boundaries of neuromyelitis optica: does antibody make the disease?

Author response: Reducing costs while enhancing quality of care in MS

Suchergebnisse filtern